Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.
Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma.
复制标题
核糖体蛋白 L22-like1 (RPL22L1) 在肝细胞癌中通过 ERK 介导索拉非尼敏感性。
DOI:
10.1038/s41420-022-01153-8
复制
发表时间:
2022-08-17
影响因子:
7
通讯作者:
Jin, Yan
中科院分区:
文献类型:
--
作者:
Zhang, Dongmei;Zhou, Yunzhen;Ma, Yanan;Jiang, Ping;Lv, Hongchao;Liu, Sijia;Mu, Yu;Zhou, Chong;Xiao, Shan;Ji, Guohua;Liu, Peng;Zhang, Ning;Sun, Donglin;Sun, Haiming;Wu, Nan;Jin, Yan
Precision medicine in hepatocellular carcinoma (HCC) relies on validated biomarkers that help subgroup patients for targeted treatment. Here, we identified a novel candidate oncogene, ribosomal protein L22-like1 (RPL22L1), which was markedly elevated in HCC, contributed to HCC malignancy and adverse patient survival. Functional studies indicated RPL22L1 overexpression accelerated cell proliferation, migration, invasion and sorafenib resistance. Mechanism studies revealed that RPL22L1 activated ERK to induce atypical epithelial-to-mesenchymal transition (EMT) progress. Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients.
登录
查看更多内容
影响因子:
3.7
作者:
Huang CJ;Yang SH;Lee CL;Cheng YC;Tai SY;Chien CC
通讯作者:
Chien CC
影响因子:
5.7
作者:
Kidger, Andrew M.;Munck, Joanne M.;Cook, Simon J.
通讯作者:
Cook, Simon J.
影响因子:
25.7
作者:
Bertuccio, Paola;Turati, Federica;Negri, Eva
通讯作者:
Negri, Eva
影响因子:
12.3
作者:
Balasubramanian S;Zheng D;Liu YJ;Fang G;Frankish A;Carriero N;Robilotto R;Cayting P;Gerstein M
通讯作者:
Gerstein M
影响因子:
2.9
作者:
Fan S;Liang Z;Gao Z;Pan Z;Han S;Liu X;Zhao C;Yang W;Pan Z;Feng W
通讯作者:
Feng W